Justificación de las excepciones al Reglamento (CE) 1967/2006 en lo referente a luz de malla, así como de la distancia a costa y profundidad marina mínima para la pesca del chanquete en la Región de Murcia.

Transparent goby fishing is an artisanal, traditional and sustainable fishery with a high economic impact for the small gear sector of the Region of Murcia. The morphological and ecological characteristics of the target species require the use of fishing gear and slaughter maneuvers not permitted in Regulation 1967/2006. For this reason, the European Commission was asked for certain exceptions for this fishery and a Management Plan was implemented. After 3 periods of exception and after 11 years of application of the Management Plan for the transparent goby fishery in the Region of Murcia, the present work demonstrates and justifies, based on the scientific data obtained in the monitoring plan, the need to the exception to Regulation (EC) 1967/2006 in relation to mesh size as well as distance to coast and minimum sea depth.La pesca del chanquete es una pesquería artesanal, tradicional y sostenible con un elevado impacto económico para el sector de artes menores de la Región de Murcia. Las características morfológicas y ecológicas de la especie objetivo exigen el uso de un arte de pesca y unas maniobras de faenado no permitidas en el Reglamento 1967/2006. Por tal motivo, se solicitó a la Comisión Europea determinadas excepciones para esta pesquería en lo referente a luz de malla, así como de la distancia a costa y profundidad marina mínima, implementándose un Plan de Gestión. Después de 3 periodos de excepción y tras 11 años de aplicación del Plan de Gestión de la pesca del chanquete en la Región de Murcia, el presente trabajo demuestra y justifica, en base a los datos científicos obtenidos en el plan de monitorización, la necesidad de la excepción al Reglamento (CE) 1967/2006 en lo referente a luz de malla, así como de la distancia a costa y profundidad marina mínima

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio